ORMP (Oramed Pharmaceuticals Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by ORMP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Avraham Gabay | Chief Financial Officer | Sell | — | — |
| 2026-07-02 | Joshua Hexter | COO & CBO | MIXED | — | — |
| 2026-03-18 | Joshua Hexter | COO & CBO | A | — | — |
| 2026-03-18 | Avraham Gabay | Chief Financial Officer | A | — | — |
| 2026-03-18 | NADAV KIDRON | President and CEO | A | — | — |
| 2026-03-18 | Miriam Kidron | Chief Scientific Officer | A | — | — |
| 2026-03-16 | NADAV KIDRON | President and CEO | G | — | — |
| 2026-01-29 | Miriam Kidron | Chief Scientific Officer | M | — | — |
| 2026-01-29 | Avraham Gabay | Chief Financial Officer | M | — | — |
| 2026-01-29 | NADAV KIDRON | President and CEO | M | — | — |
| 2026-01-29 | Joshua Hexter | COO & CBO | M | — | — |
| 2026-01-21 | Miriam Kidron | Chief Scientific Officer | G | — | — |
| 2026-01-05 | Arie Mayer | Director | A | — | — |
| 2026-01-05 | Yehuda Reznick | Director | A | — | — |
| 2026-01-05 | Joshua Hexter | COO & CBO | A | — | — |
| 2026-01-05 | Miriam Kidron | Chief Scientific Officer | A | — | — |
| 2026-01-05 | NADAV KIDRON | President and CEO | A | — | — |
| 2026-01-05 | Benjamin Shapiro | Director | A | — | — |
| 2026-01-02 | Daniel Aghion | Director | A | — | — |
| 2026-01-02 | Avraham Gabay | Chief Financial Officer | A | — | — |
| 2025-06-09 | Leonard Sank | Director | A | — | — |
| 2025-06-09 | Yehuda Reznick | Director | A | — | — |
| 2025-06-09 | Daniel Aghion | Director | A | — | — |
| 2025-06-09 | Arie Mayer | Director | A | — | — |
| 2025-06-09 | Benjamin Shapiro | Director | A | — | — |
| 2025-02-11 | NADAV KIDRON | President and CEO | A | — | — |
| 2025-02-11 | Joshua Hexter | COO & CBO | A | — | — |
| 2025-02-11 | Miriam Kidron | Chief Scientific Officer | A | — | — |
| 2025-02-11 | Avraham Gabay | Chief Financial Officer | A | — | — |
| 2025-01-06 | Miriam Kidron | Chief Scientific Officer | A | — | — |
| 2025-01-06 | Joshua Hexter | COO & CBO | A | — | — |
| 2025-01-06 | Avraham Gabay | Chief Financial Officer | A | — | — |
| 2025-01-06 | NADAV KIDRON | President and CEO | A | — | — |
| 2024-11-08 | Avraham Gabay | Chief Financial Officer | A | — | — |
| 2024-11-08 | Miriam Kidron | Chief Scientific Officer | A | — | — |
| 2024-11-08 | Joshua Hexter | COO & CBO | A | — | — |
| 2024-11-08 | NADAV KIDRON | President and CEO | A | — | — |
| 2024-06-21 | Avraham Gabay | Chief Financial Officer | A | — | — |
| 2024-06-10 | Yehuda Reznick | Director | A | — | — |
| 2024-04-18 | Yehuda Reznick | Director | A | — | — |
| 2024-01-30 | Daniel Aghion | Director | A | — | — |
| 2024-01-08 | David Silberman | Chief Financial Officer | A | — | — |
| 2024-01-08 | Joshua Hexter | COO & CBO | A | — | — |
| 2024-01-08 | NADAV KIDRON | President and CEO | A | — | — |
| 2024-01-08 | Daniel Aghion | Director | A | — | — |
| 2024-01-08 | Benjamin Shapiro | Director | A | — | — |
| 2024-01-08 | Yadin Rozov | Director | A | — | — |
| 2024-01-08 | Leonard Sank | Director | A | — | — |
| 2024-01-08 | Miriam Kidron | Chief Scientific Officer | A | — | — |
| 2024-01-08 | Arie Mayer | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 3,548,243 | — |
| — | Director | 2,019,720 | — |
| — | Chief Scientific Officer | 1,568,222 | — |
| — | Director | 1,316,328 | — |
| — | 10%+ Owner | 1,186,823 | — |
| — | COO & CBO | 1,073,384 | — |
| — | 10%+ Owner | 896,364 | — |
| — | Chief Financial Officer | 671,785 | — |
| — | Chief Financial Officer | 366,500 | — |
| — | Director | 266,910 | — |
| — | Director | 206,350 | — |
| — | Director | 168,009 | — |
| — | Director | 155,320 | — |
| — | Chief Legal Officer | 149,500 | — |
| — | Chief Commercial Officer | 126,143 | — |
| — | Chief Commercial Officer | 109,468 | — |
| — | Director | 107,191 | — |
| — | Director | 105,180 | — |
| — | Director | 46,661 | — |
| — | CFO, Treasurer and Secretary | 46,560 | — |
| — | Director | 24,896 | — |
| — | Director | 22,896 | — |
| — | Director | 17,096 | — |
| — | Director | 16,191 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ORMP quote page; the site-wide leaderboard is on the insider transactions hub.